Elanco Animal Health (NYSE:ELAN) Posts Earnings Results, Misses Estimates By $0.01 EPS

Elanco Animal Health (NYSE:ELAN) issued its quarterly earnings data on Tuesday. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01), Zacks reports. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the business posted $0.08 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $11.15 on Thursday. The stock’s fifty day simple moving average is $11.74 and its 200 day simple moving average is $13.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 27.88, a P/E/G ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a one year low of $10.20 and a one year high of $18.80.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ELAN. Barclays cut their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday. UBS Group dropped their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Morgan Stanley dropped their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and a consensus price target of $15.57.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.